LOXL2 and breast cancer: In contrast, in a mouse model of breast cancer, while the number of tumor-associated endothelial cells was reduced by the LOXL2 targeted antibody AB0023, microvessel density was not significantly modulated by M64, a LOX-specific antibody raised against LOX catalytic domain, supporting a major role of LOXL2 on tumor neovascularization [89].